Lionco Pharmaceutical Group Co (SHSE:603669) Debt-to-Equity

: 0.63 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

Lionco Pharmaceutical Group Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ¥218.5 Mil. Lionco Pharmaceutical Group Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ¥436.6 Mil. Lionco Pharmaceutical Group Co's Total Stockholders Equity for the quarter that ended in Sep. 2023 was ¥1,034.8 Mil. Lionco Pharmaceutical Group Co's debt to equity for the quarter that ended in Sep. 2023 was 0.63.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Lionco Pharmaceutical Group Co's Debt-to-Equity or its related term are showing as below:

SHSE:603669' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.35 Max: 0.86
Current: 0.63

During the past 12 years, the highest Debt-to-Equity Ratio of Lionco Pharmaceutical Group Co was 0.86. The lowest was 0.05. And the median was 0.35.

SHSE:603669's Debt-to-Equity is ranked worse than
73.78% of 858 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs SHSE:603669: 0.63

Lionco Pharmaceutical Group Co Debt-to-Equity Historical Data

The historical data trend for Lionco Pharmaceutical Group Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lionco Pharmaceutical Group Co Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

0.29

0.19

0.74

0.65

0.55

Lionco Pharmaceutical Group Co Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity																0.40	0.55	0.61	0.61	0.63

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lionco Pharmaceutical Group Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lionco Pharmaceutical Group Co Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Lionco Pharmaceutical Group Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Lionco Pharmaceutical Group Co's Debt-to-Equity falls into.

Lionco Pharmaceutical Group Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Lionco Pharmaceutical Group Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(206.386	+	413.589)	/	1135.144
	=	0.55

Lionco Pharmaceutical Group Co's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(218.504	+	436.619)	/	1034.816
	=	0.63

Lionco Pharmaceutical Group Co (SHSE:603669) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Lionco Pharmaceutical Group Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Lionco Pharmaceutical Group Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Lionco Pharmaceutical Group Co (SHSE:603669) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lionco Pharmaceutical Group Co Ltd (SHSE:603669) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

68 Zetang Nedong commercial building, 2nd Floor, Shannan Prefecture, CHN

Website

http://www.lingkang.com.cn

Lionco Pharmaceutical Group Co Ltd is engaged in the research and development of medicines. The product portfolio includes - Alanyl glutamine for injection, fructose for injection, inverted sugar for injection, xylitol for injection, riboflavin sodium phosphate for injection, and water-soluble vitamin for injection.

Lionco Pharmaceutical Group Co (SHSE:603669) Headlines

No Headlines